- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Suven Life Sciences to Present Phase 3 Masupirdine, Phase 1 Tenaclidine Data at Alzheimer's Conference

Hyderabad: Suven Life Sciences will present clinical data on its investigational drug candidates Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107) at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, being held in Boston, US, from November 16 to 19, 2026.
The two scientific presentations will highlight the clinical progress of the company's candidates being developed for central nervous system (CNS) disorders, including Alzheimer's disease and cognitive disorders.
In a presentation titled "Masupirdine (SUVN-502), A Pure 5-HT6 Receptor Antagonist: Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type" (P033), Suven will present baseline demographic and clinical characteristics of patients enrolled in its global Phase 3 study of Masupirdine for agitation associated with Alzheimer's disease dementia.
The company will also present findings from the Phase 1 evaluation of Tenaclidine, a pure M1 positive allosteric modulator, in healthy subjects. The presentation, titled "Tenaclidine (SUVN-I6107), A Pure M1 Positive Allosteric Modulator: First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects" (P066), will cover outcomes from single ascending dose (SAD) and multiple ascending dose (MAD) studies.
The Tenaclidine findings will include data on safety, tolerability and pharmacokinetics, along with the effects of food, age and gender on its pharmacokinetic profile.
Commenting on the presentations, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said completion of enrolment in the global Phase 3 Masupirdine study marked an important milestone in the candidate's clinical development. He said the baseline characteristics were consistent with published studies and represented a quality Alzheimer's disease population with agitation, adding that no major safety concerns had been identified to date.
The company expects to report topline results from the Masupirdine Phase 3 study in the second quarter of 2027.
Jasti also said Suven was encouraged by the clinical findings for Tenaclidine and planned to advance the candidate to patient studies.
Suven Life Sciences is focused on discovering and developing medicines for unmet medical needs in CNS disorders. Its clinical-stage pipeline includes Masupirdine for agitation in Alzheimer's disease dementia, Samelisant for excessive daytime sleepiness in narcolepsy, Ropanicant for major depressive disorder, and Usmarapride and Tenaclidine for cognitive disorders.
The company has completed enrolment in the global Phase 3 study of Masupirdine. Its pipeline also includes seven research-stage projects across multiple indications.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

